Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1) medication
None of these are changes a patient makes independently
The escalation phases are only required during the first cycle

Thorpe KM, Patel C, Harrison R, Eapen Z, Ambrosy A, Coker R, Jenkins W, Anderson M, Migdalis I, Eliasson B, Chiang C, Cuadrado J, Santos NG, Litvak M, Loureyro J, Maldonado N, Gaal LV, Mihaylova-Shumkova R, Akhras R, Grondin F, Gupta M, Jones M, Lonn E, Lastuvka J, Cadinot D, Chevts J, Grosskopf J, Heymer P, Jung T, Luedemann J, Maxeiner S, Milek K, Regner S, Rieker W, Seufert J, Dimitriadis G, Pagkalos E, Mucsi J, Bonadonna R, Cosmo SE, Ponzani P, Trevisan R, Jang HC, Lee EY, Yu J, Vidrio-Velzquez M, Viergever EP, Guttormsen G, Wium C, Gadzinski W, Krzyzagorska E, Madej A, Romanczuk P, Garganeeva A, Kharakhulakh M, Lesnov V, Vasilevskaya O, Dawood S, Calonge AN, Charneco MQ, Rodrguez IR, Lundman P, Sderberg S, Chen JF, Sansanayudh N, Zlova T, Cookson T, Akhter F, Baum H, Aguiar RBD, Cheung D, Cohen A, Farris N, Forgosh L, Hartman I, Hermany P, Kulback S, Labroo A, Little R, Mehta A, Moran J, Rasouli N, Tan M, Wynne A, Yazdani S, Stewart M, Patel P, Sabol MB, Casson E, Hereghty B, Fernandez-Salazar E, Donaldson J, Jarosz M, Richards J, McLaughlin P, Breneman J, Shitut A, Bhosale A, Naicker P, Dumbre S

Accessibility: Compounding pharmacies can make semaglutide more available, especially during shortages or when standard formulations are hard to find
Presented for research literature review only Modak AK et al